MAPT and Alzheimer disease: These findings are in line with previous studies reporting up‐regulation of cerebral ICAM1 in a number of AD transgenic models (Ferretti et al., 2016) and, moreover, correlations with Aβ and tau pathology in human AD patients (Walker et al., 2017).